A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial ...
An important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that ...